



Access & Integration,
Room 138, Dr. Steevens' Hospital, Dublin 8.
D08 W2A8

13th August 2024

Mr Michael Lowry TD,
Dáil Éireann,
Leinster House,
Kildare Street,
Dublin 2.

PQ 30919/24: To ask the Minister for Health how the decision to reduce the reimbursement rate for cataract surgery from €1,928 to €863, through the cross-Border healthcare scheme aligns with the Government's commitment to ensuring accessible and affordable healthcare for all citizens (details supplied); and if he will make a statement on the matter

Dear Deputy Lowry

Thank you for your Parliamentary Question referenced above, which has been forwarded to me for direct reply.

Individuals may choose to access Overseas Treatment Schemes, the schemes are not part of State based healthcare access pathways and management. The decision on reimbursement rates relates to Activity Based Funding (ABF) which is the main mechanism by which funding is allocated to Irish acute public hospitals. ABF seeks to fund hospitals based on the number and mix of patients treated in those hospitals. Diagnosis Related Groups (DRGs) are the means by which patients are classified to allow like for like comparison of patient profiles between hospitals.

The Healthcare Pricing Office (HPO) within the HSE, using an Australian AR-DRG classification system, sets prices for all 795 DRGs based on the average cost of all public hospitals with activity in that DRG, using HIPE activity data and costing data. The price list is primarily used to determine the cost of activity in public hospitals. The HSE's Overseas Treatment Schemes office uses this HPO costing for the purpose of reimbursing service users for procedures done overseas and in Northern Ireland.

The DRG price list has changed in 2024 across the Irish public health system to reflect an update in the Australian AR-DRG Classification System. The price list has also changed to reflect the availability of costing data for the Activity Based Funding 2024 price for the first time in a number of years due to the impact of COVID-19. There has been a reclassification of certain cataract procedures following the international coding system (Australian AR-DRG Classification System), in which some prices have increased and some have decreased.

HPO prices were due to change effective from 1 July 2024. In order to ensure no one is disadvantaged and communicate fully with service users, treating consultants and providers the HSE is deferring the application of these cost changes for the purposes of reimbursement of cataract procedures until 1st September 2024. During this time, we will communicate with providers in Northern Ireland and patients to advise them of the amended prices for cataract procedures.

Yours sincerely,



Frances McNamara
Assistant National Director